Teva Pharmaceutical Indus... (TEVA)
Teva Pharmaceutical Industries Limited Statistics
Share Statistics
Teva Pharmaceutical Industries Limited has 1.13B shares outstanding. The number of shares has increased by 1.21% in one year.
| Shares Outstanding | 1.13B |
| Shares Change (YoY) | 1.21% |
| Shares Change (QoQ) | 0.14% |
| Owned by Institutions (%) | 56.08% |
| Shares Floating | 1.13B |
| Failed to Deliver (FTD) Shares | 75 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 15.80M, so 1.39% of the outstanding shares have been sold short.
| Short Interest | 15.80M |
| Short % of Shares Out | 1.39% |
| Short % of Float | 1.39% |
| Short Ratio (days to cover) | 1.26 |
Valuation Ratios
The PE ratio is -15.43 and the forward PE ratio is 6.55. Teva Pharmaceutical Industries Limited's PEG ratio is -0.08.
| PE Ratio | -15.43 |
| Forward PE | 6.55 |
| PS Ratio | 1.53 |
| Forward PS | 1.2 |
| PB Ratio | 4.71 |
| P/FCF Ratio | 33.76 |
| PEG Ratio | -0.08 |
Enterprise Valuation
Teva Pharmaceutical Industries Limited has an Enterprise Value (EV) of 28.61B.
| EV / Earnings | -17.46 |
| EV / Sales | 1.73 |
| EV / EBITDA | -94.42 |
| EV / EBIT | -94.42 |
| EV / FCF | 38.2 |
Financial Position
The company has a current ratio of 0.98, with a Debt / Equity ratio of 3.36.
| Current Ratio | 0.98 |
| Quick Ratio | 0.75 |
| Debt / Equity | 3.36 |
| Total Debt / Capitalization | 77.09 |
| Cash Flow / Debt | 0.07 |
| Interest Coverage | -0.3 |
Financial Efficiency
Return on equity (ROE) is -0.31% and return on capital (ROIC) is -1.63%.
| Return on Equity (ROE) | -0.31% |
| Return on Assets (ROA) | -0.04% |
| Return on Capital (ROIC) | -1.63% |
| Revenue Per Employee | 488.14K |
| Profits Per Employee | -48.36K |
| Employee Count | 33.89K |
| Asset Turnover | 0.42 |
| Inventory Turnover | 2.82 |
Taxes
| Income Tax | 355.00M |
| Effective Tax Rate | -0.53 |
Stock Price Statistics
The stock price has increased by 30.92% in the last 52 weeks. The beta is 0.71, so Teva Pharmaceutical Industries Limited's price volatility has been higher than the market average.
| Beta | 0.71 |
| 52-Week Price Change | 30.92% |
| 50-Day Moving Average | 19.57 |
| 200-Day Moving Average | 17.82 |
| Relative Strength Index (RSI) | 38.73 |
| Average Volume (20 Days) | 12.28M |
Income Statement
In the last 12 months, Teva Pharmaceutical Industries Limited had revenue of 16.54B and earned -1.64B in profits. Earnings per share was -1.45.
| Revenue | 16.54B |
| Gross Profit | 8.06B |
| Operating Income | -303.00M |
| Net Income | -1.64B |
| EBITDA | -303.00M |
| EBIT | -303.00M |
| Earnings Per Share (EPS) | -1.45 |
Balance Sheet
The company has 3.30B in cash and 18.08B in debt, giving a net cash position of -14.78B.
| Cash & Cash Equivalents | 3.30B |
| Total Debt | 18.08B |
| Net Cash | -14.78B |
| Retained Earnings | -15.17B |
| Total Assets | 39.33B |
| Working Capital | -244.00M |
Cash Flow
In the last 12 months, operating cash flow was 1.25B and capital expenditures -498.00M, giving a free cash flow of 749.00M.
| Operating Cash Flow | 1.25B |
| Capital Expenditures | -498.00M |
| Free Cash Flow | 749.00M |
| FCF Per Share | 0.66 |
Margins
Gross margin is 48.74%, with operating and profit margins of -1.83% and -9.91%.
| Gross Margin | 48.74% |
| Operating Margin | -1.83% |
| Pretax Margin | -7.76% |
| Profit Margin | -9.91% |
| EBITDA Margin | -1.83% |
| EBIT Margin | -1.83% |
| FCF Margin | 4.53% |
Dividends & Yields
TEVA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -8.52% |
| FCF Yield | 3.88% |
Analyst Forecast
The average price target for TEVA is $24.5, which is 43.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $24.5 |
| Price Target Difference | 43.9% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Jul 1, 2004. It was a forward split with a ratio of 2:1.
| Last Split Date | Jul 1, 2004 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 0.74 |
| Piotroski F-Score | 4 |